102. ルビンシュタイン・テイビ症候群 Disease details / Clinical trials / Drug dev / DR info
臨床試験数 : 4 / 薬物数 : 8 - (DrugBank : 0) / 標的遺伝子数 : 0 - 標的パスウェイ数 : 0
薬物、開発者(Primary Sponsor)、臨床試験情報(症例登録開始年(Enrollment year)、フェーズ、ID、実施国)
Culture OF lymphoblastoid line from blood sample
University Hospital, Bordeaux
2019 - NCT04122742 France
Depakine
CHU de bordeaux
- Phase 2 EUCTR2011-003784-30-FR France
EX-vivo approach concerning 25 patients
University Hospital, Bordeaux
2023 - NCT05696912 France
Functional involvement OF identified epigenetic alterations
University Hospital, Bordeaux
2019 - NCT04122742 France
Generation OF induced pluripotent stem cells (ipsc) from fibroblasts obtained BY skin biopsy
University Hospital, Bordeaux
2019 - NCT04122742 France
Histone acetylation profiles OF cells OF SRT patients with crebbp mutations
University Hospital, Bordeaux
2019 - NCT04122742 France
IN-vitro approach concerning 25 patients
University Hospital, Bordeaux
2023 - NCT05696912 France
Sodium valproate
University Hospital, Bordeaux
2012 Phase 2 NCT01619644 France
University Hospital, Bordeaux
2019 - NCT04122742 France
Depakine
CHU de bordeaux
- Phase 2 EUCTR2011-003784-30-FR France
EX-vivo approach concerning 25 patients
University Hospital, Bordeaux
2023 - NCT05696912 France
Functional involvement OF identified epigenetic alterations
University Hospital, Bordeaux
2019 - NCT04122742 France
Generation OF induced pluripotent stem cells (ipsc) from fibroblasts obtained BY skin biopsy
University Hospital, Bordeaux
2019 - NCT04122742 France
Histone acetylation profiles OF cells OF SRT patients with crebbp mutations
University Hospital, Bordeaux
2019 - NCT04122742 France
IN-vitro approach concerning 25 patients
University Hospital, Bordeaux
2023 - NCT05696912 France
Sodium valproate
University Hospital, Bordeaux
2012 Phase 2 NCT01619644 France